Month: April 2020

ASi Tallinna Vesi 2020. aasta esimese kvartali müügitulud kahanesid võrreldes 2019. aasta sama perioodiga 10,1% ja ulatusid 13,18 miljoni euro tasemele. Alates 01. detsembrist 2019. aastal langesid põhitegevuspiirkonna eraklientide joogivee ja reovee ärajuhtimise teenuste tariifid keskmiselt 27% ning äriklientide tariifid 15%.Võrreldes möödunud aastaga suurenes 2020. aasta esimeses kvartalis kogu veetarbimine, ent alates märtsi teisest poolest on koroonaviiruse mõju olnud tarbimismahtudele vastupidine. Eraklientide müügitulud vähenesid 2020. aasta esimeses kvartalis peamiselt tulenevalt 27% madalamast tariifist 22,6%. Samal ajal kasvasid eraklientide tarbimismahud. Äriklientide müügitulud vähenesid võrreldes möödunud aasta esimese kvartaliga 17,1%. Äriklientide tariifid langesid 2019. aasta detsembrist 15% võrra ning alates märtsi teisest...

Sanofi at forefront of fight against COVID-19 in Q1 2020(1) Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9); (2) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q1 2020 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (3) Base for business EPS growth is €5.97, reflecting 2 cents impact from IFRS 16 (Appendix 9); (4) Free cash flow is a non-GAAP financial measure (definition in Appendix 9).2020 first-quarter Sanofi salesIn the first quarter of 2020, Company sales were €8,973 million, up 6.9% on a reported...

Sanofi à la pointe du combat contre la pandémie de COVID‑19 au T1 2020(1) Sauf indication contraire, l’évolution du CA est exprimée à taux de change constants (TCC) (voir Annexe 9); (2) Le commentaire du compte de résultat net des activités, indicateur non-GAAP, permet de rendre compte de la performance économique de Sanofi (voir définition à l’Annexe 9). Le compte de résultats consolidés du T1 2020 figure en Annexe 3. Le passage du résultat net IFRS au résultat net des activités est en Annexe 4 ; (3) La base 2020 est un BNPA des activités de €5,97 après impact de 2 cents liés à l’application d’IFRS 16 (voir Annexe 9), (4) Le Cash flow libre est un indicateur non-GAAP (voir définition à l’Annexe 9).Chiffre d’affaires de Sanofi du premier trimestre 2020Au premier trimestre 2020, le chiffre d’affaires de Sanofi a atteint 8 973 millions...

» For a comparable portfolio, i.e. properties owned for the whole of 2019 and 2020, income increased by 4 per cent to SEK 805 million (773) and the operating surplus increased by 8 per cent to SEK 539 million (501).Statement by the CEOA strong first quarter despite the current situationDespite a turbulent start to 2020, marked by covid-19, earnings have been strong during the first quarter. This is partly due to a mild winter but also due to a good development in a comparable portfolio. The quarter gives us a safer starting point ahead of the rest of the year. From mid-March onwards the focus has been on parrying the effects of the current corona situation, among others through a longterm constructive dialogue with tenants in particularly affected industries.STABLE EARNINGS DEVELOPMENTKlövern is reporting stable and good earnings for...

» I jämförbart bestånd, dvs fastigheter som ägts under hela 2019 och 2020, ökade intäkterna med 4 procent till 805 mkr (773) medan driftöverskottet ökade med 8 procent till 539 mkr (501).» De redovisade intäkterna uppgick till 837 mkr (896) medan driftöverskottet uppgick till 558 mkr (599). Minskningen beror på nettoförsäljning av fastigheter under 2019, bland annat hela beståndet i Karlstad och samtliga förvaltningsfastigheter i Örebro.» Förvaltningsresultatet uppgick till 324 mkr (362).» Resultatet före skatt uppgick till 882 mkr (847) och resultatet efter skatt, hänförligt till moderbolagets aktieägare, uppgick till 656 mkr (632) motsvarande 0,70 kr (0,67) per stamaktie.» Värdeförändringar på fastigheter uppgick till 593 mkr (544).» Projektutveckling, inklusive utveckling av byggrätter, bidrog med värdeökningar på fastigheter om 97...

INTERIM REPORT for 1 January – 31 March 2020: Strong profitability improvement while outgrowing the marketVerkkokauppa.com Oyj – Interim report (unaudited) 24 March 2020, 8:00 a.m.1 January – 31 March 2020 in briefRevenue 125 million euros (1–3/2019: 116), growth of 8.2%Gross profit 19.4 million euros (17.4), growth of 11.6%Gross margin 15.5% of revenue (15.0%)Operating profit 3.4 million euros (2.3)Operating margin 2.7% of revenue (2.0%)Comparable operating profit 3.8 million euros (2.3)Comparable operating margin 3.0% (2.0%)Profit for the period 2.4 million euros (1.5)Earnings per share 0.05 euros (0.03)Investments 0.3 million euros (0.1)Operating cash flow 3.7 million euros (-11.2)The Board of Directors has resolved to pay after the reporting period a quarterly dividend of 0.053 euros per share             BUSINESS OUTLOOKVerkkokauppa.com...

OSAVUOSIKATSAUS 1.1.–31.3.2020: Vahva kannattavuuden kasvu, markkinaosuuden kasvaessa Verkkokauppa.com Oyj – osavuosikatsaus (tilintarkastamaton) 24.4.2020 klo 8.001.1.–31.3.2020 lyhyestiLiikevaihto 125 miljoonaa euroa (1–3/2019:116), kasvua 8,2 %Myyntikate 19,4 miljoonaa euroa (17,4), kasvua 11,6 %Myyntikate 15,5 % liikevaihdosta (15,0 %)Liiketulos 3,4 miljoonaa euroa (2,3)Liiketulosprosentti 2,7% liikevaihdosta (2,0%)Vertailukelpoinen liiketulos 3,8 miljoonaa euroa (2,3)Vertailukelpoinen liiketulosprosentti 3,0% liikevaihdosta (2,0%)Katsauskauden tulos 2,4 miljoonaa euroa (1,5)Osakekohtainen tulos 0,05 euroa (0,03)Investoinnit 0,3 miljoonaa euroa (0,1)Liiketoiminnan kassavirta 3,7 miljoonaa euroa (-11,2)Yhtiön hallitus on hyväksynyt katsauskauden jälkeen toisen vuosineljänneksen osingon 0,053 euroa osaketta kohti             TULEVAISUUDEN...

FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.Safety and effectiveness studied in five double-blind, randomized clinical trials with nearly 5,000 individualsHelps protect an expanded age group and elicits a high immune response across multiple agesUnder regulatory review in Europe and other countries to help support local immunization efforts                   PARIS – April 24, 2020 – The U.S. Food and Drug Administration (FDA) has approved a Biologics License Application for MenQuadfiTM Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older.“Meningococcal meningitis remains a major global...

La FDA approuve MenQuadfiTM, la toute dernière innovation en matière de vaccin méningococcique (MenACWY)                                                                                                                                                           Toute dernière innovation en matière de vaccin méningococcique quadrivalent pour la vaccination dès l’âge de 2 ans aux États-UnisProfil de sécurité et d’efficacité étudié dans le cadre de cinq essais cliniques randomisés, en double aveugle, ayant recruté près de 5 000 sujetsPermet de protéger une large tranche d’âge avec une réponse immunitaire élevéeSoumis pour approbation en Europe et dans d’autres pays pour répondre aux efforts de prévention mis en œuvre localement                     PARIS – Le 24 avril 2020 – La Food and Drug Administration (FDA) des États-Unis a approuvé la...

Lassila & Tikanoja plcInside information24 April 2020 at 8:00Profit warning: Lassila & Tikanoja plc lowers its guidance for 2020 due to the shutdown of Russian operations and the coronavirus epidemicLassila & Tikanoja plc is changing its guidance for 2020 due to the discontinuation of Russian operations and the coronavirus epidemic.The new outlook:Full-year net sales for 2020 are expected to decrease year-on-year and operating profit is estimated to be EUR 30–40 million (40.5) excluding loss related to the discontinuation of Russian operations.Due to the reforms in waste management carried out by the state of Russia in 2019, the implementation of waste management in the Moscow region was allocated to seven operators. As a result of this change, the area in which Lassila & Tikanoja operates was allocated to two operators....